TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16821257

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 114
Study: 15575809

Group type: EXPERIMENTAL
Intervention: Conditioned lenses with carboxymethylcellulose (CMC)
Number of subjects: 61
Study: 10770306

Group type: EXPERIMENTAL
Intervention: PBSC
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bone Marrow
Number of subjects: 39
Study: 9293310

Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted vaginal hysterectomy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 22
Study: 8223838

Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg once daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rilmenidine 2 mg once daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rilmenidine 0.5 mg once daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2939197

Group type: EXPERIMENTAL
Intervention: HEVAC B vaccine
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: GCC VAC vaccine
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Relationship to index carrier
Number of subjects: 214
Study: 30136707

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray at 200 microgram once daily for 3 months
Number of subjects: 187

Group type: COMPARATOR
Intervention: Clarithromycin tablet at 250 mg once daily for 3 months
Number of subjects: 187
Study: 28697803

Group type: EXPERIMENTAL
Intervention: Physical activity and nutrition program (intervention group)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 363
Study: 25711157

Group type: EXPERIMENTAL
Intervention: Gyrus ACMI/Olympus Invisio DUR-D
Number of subjects: 101

Group type: COMPARATOR
Intervention: Olympus URF-V
Number of subjects: 101
Study: 24335582

Group type: EXPERIMENTAL
Intervention: Testing 1 hour before dialysis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Testing during the first hour of dialysis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both testing periods
Number of subjects: 40
Study: 20803028

Group type: EXPERIMENTAL
Intervention: Myofeedback training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intensive muscular strength training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 19155592

Group type: EXPERIMENTAL
Intervention: 7.5 g D-psicose alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: 75 g maltodextrin alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 75 g maltodextrin + 2.5 g D-psicose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 75 g maltodextrin + 5 g D-psicose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 75 g maltodextrin + 7.5 g D-psicose
Number of subjects: 20
Study: 16753648

Group type: EXPERIMENTAL
Intervention: Detoxification (DTX)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Not in treatment (NT)
Number of subjects: 243
Study: 12663312

Group type: EXPERIMENTAL
Intervention: Shortened version of computer-based instruction (less than 1.5 hours)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Full version of computer-based instruction (2.5 hours)
Number of subjects: 117
Study: 10506661

Group type: EXPERIMENTAL
Intervention: Random peptide libraries (RPLs) screening with IDDM sera
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CH1p mimotope
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimentally raised anti-osteopontin antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cDNA library screening
Number of subjects: 0
Study: 8932874

Group type: EXPERIMENTAL
Intervention: ICI182780 6 mg/day (n = 10) for 7 days
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tamoxifen (4 x 40 mg on day 1, 20 mg/day thereafter, median 21 days) (n = 8)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no preoperative treatment n = 9, placebo n = 7)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ICI182780
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 1992531

Group type: EXPERIMENTAL
Intervention: Carboplatin 60 mg/m2 with 67.2 Gy radiation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carboplatin 50 mg/m2 with 67.2 Gy radiation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carboplatin (various doses) with 58.8 Gy radiation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Carboplatin (various doses) with radiation
Number of subjects: 36
Study: 6342396

Group type: EXPERIMENTAL
Intervention: Trial of labor
Number of subjects: 105

Group type: COMPARATOR
Intervention: Elective cesarean section
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Trial of labor and Elective cesarean section
Number of subjects: 105
Study: 30811872

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (n = 133)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (n = 67)
Number of subjects: 200
Study: 30788944

Group type: EXPERIMENTAL
Intervention: 20 m×5 shuttle runs at dominant side
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 m×5 shuttle runs at non-dominant side
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 m×10 shuttle runs at dominant side
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 m×10 shuttle runs at non-dominant side
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All exercise loads
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Recovery period (20 minutes)
Number of subjects: 10
Study: 27234480

Group type: EXPERIMENTAL
Intervention: eCMP (Electronic Cardio-Metabolic Program) for 6 months
Number of subjects: 74
Study: 25107840

Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer (CIK) cell treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CIK treatment)
Number of subjects: 0
Study: 22897472

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Environments (IVE) with manipulated ostracism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 20838741

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily in ambulatory patients
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily in non-ambulatory patients
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Placebo in ambulatory patients
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Placebo in non-ambulatory patients
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Enoxaparin vs. placebo in ambulatory patients
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Enoxaparin vs. placebo in non-ambulatory patients
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: History of VTE
Number of subjects: 1084

Group type: EXPERIMENTAL
Intervention: Cancer
Number of subjects: 1084
Study: 18269820

Group type: EXPERIMENTAL
Intervention: Primary PCI combined with tirofiban therapy (Tirofiban group, n = 80)
Number of subjects: 160
Study: 15386821

Group type: EXPERIMENTAL
Intervention: Metformin plus pioglitazone (15 mg o.d. titrated up to 45 mg)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Metformin plus gliclazide (80 mg o.d. titrated up to 320 mg)
Number of subjects: 630
Study: 11870502

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with sequential subcutaneous IL-2 and IFN-alpha
Number of subjects: 124

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 124
Study: 10354810

Group type: EXPERIMENTAL
Intervention: Active viewing task (aDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive viewing into darkness (pDF)
Number of subjects: 0
Study: 7492852

Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) analysis of articulatory characteristics for /s, f, tf/
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) analysis of /t/
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) data
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) analysis
Number of subjects: 10
Study: 1722310

Group type: EXPERIMENTAL
Intervention: recombinant methionyl human granulocyte colony-stimulating factor (r-met-GCSF)
Number of subjects: 10
Study: 7045016

Group type: EXPERIMENTAL
Intervention: Single daily doses of amoxapine (dosage not specified)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Divided daily doses of amoxapine (dosage not specified)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Amoxapine (50 and 100 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg)
Number of subjects: 35
Study: 31426864

Group type: EXPERIMENTAL
Intervention: Radiomics signature based on 18F-FDG-PET
Number of subjects: 107
Study: 28707168

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 28
Study: 26334096

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/kg2 iv)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gemcitabine with Pegintron (1 μg/kg sc)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gemcitabine with Pegintron and p53 SLP vaccine (0.3 mg/peptide, 9 peptides)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 15
Study: 24597729

Group type: EXPERIMENTAL
Intervention: Head Start
Number of subjects: 3185
Study: 22643801

Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation (Joint Care®) with group therapy, early mobilization (same day as surgery), and 1:1 physiotherapy (2 h/day)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard rehabilitation with individual postoperative care and 1:1 physiotherapy (1 h/day)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation
Number of subjects: 147
Study: 20070721

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) detection using a radioactive tracer and blue dye; followed by radical vulvectomy or radical wide excision with uni/bilateral inguinofemoral lymphadenectomy.
Number of subjects: 23
Study: 17317391

Group type: EXPERIMENTAL
Intervention: CVD risk factors (older age)
Number of subjects: 4288

Group type: EXPERIMENTAL
Intervention: CVD risk factors (pack years smoked)
Number of subjects: 4288

Group type: EXPERIMENTAL
Intervention: CVD risk factors (systolic blood pressure)
Number of subjects: 4288

Group type: EXPERIMENTAL
Intervention: CVD treatment (calcium channel blockers)
Number of subjects: 4288

Group type: EXPERIMENTAL
Intervention: CVD risk factors (self‐reported history of diabetes)
Number of subjects: 4288

Group type: EXPERIMENTAL
Intervention: CVD risk factors (body mass index)
Number of subjects: 4288
Study: 15546229

Group type: EXPERIMENTAL
Intervention: Parental involvement, monitoring, and expectations
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Initial smoking stage
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Initial number of friends who smoked
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Associations over time among smoking stage progression, affiliation with friends who smoke, and parenting behaviors
Number of subjects: 1320
Study: 11426631

Group type: EXPERIMENTAL
Intervention: 9‐cis‐retinoic acid (9‐cis RA) 100 mg/m2 orally once daily after initial 70 mg/m2 twice a day for the first three patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 9‐cis‐retinoic acid (9‐cis RA)
Number of subjects: 29
Study: 9362390

Group type: EXPERIMENTAL
Intervention: 12 months of interferon therapy (IFN), 3-5 MU three times weekly
Number of subjects: 79

Group type: COMPARATOR
Intervention: 6 months of observation followed by 6 months of IFN therapy
Number of subjects: 79
Study: 1318845

Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25-50 mg
Number of subjects: 16
Study: 4032324

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy (12 sessions)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cognitively orientated supportive psychotherapy (6 sessions)
Number of subjects: 26
Study: 3237434

Group type: EXPERIMENTAL
Intervention: Biofeedback down-training
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biofeedback up-training
Number of subjects: 10
Study: 30697949

Group type: EXPERIMENTAL
Intervention: Index of Facial Pain Expression (IFPE) training
Number of subjects: 54

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 54
Study: 28750893

Group type: EXPERIMENTAL
Intervention: CSE3104
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSE3165
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citric acid buffer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human taste assessments
Number of subjects: 0
Study: 26727841

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14523
Study: 24339936

Group type: EXPERIMENTAL
Intervention: Group B: 80 kVp and contrast media of 270 mgI/ml with iterative reconstruction algorithm
Number of subjects: 92

Group type: COMPARATOR
Intervention: Group A: 120 kVp and contrast media of 320 mgI/ml
Number of subjects: 92
Study: 20523219

Group type: EXPERIMENTAL
Intervention: Chronic aspirin therapy
Number of subjects: 11313

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 11313

Group type: COMPARATOR
Intervention: Chronic antiplatelet therapy (single or dual)
Number of subjects: 11313
Study: 18305461

Group type: EXPERIMENTAL
Intervention: Caffeine 150 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Caffeine 450 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Caffeine 0 mg
Number of subjects: 102
Study: 16418843

Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the left dorsolateral prefrontal cortex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 0
Study: 14505767

Group type: EXPERIMENTAL
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: As-treated analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherers-only analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imputation of missing values
Number of subjects: 0
Study: 10752914

Group type: EXPERIMENTAL
Intervention: Partial mattress encasing with a nylon sheet underneath regular cotton bed sheets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular cotton bed sheets (Control Group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nylon sheet barrier
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular cotton bed sheet
Number of subjects: 60
Study: 8882988

Group type: EXPERIMENTAL
Intervention: Etoposide 200 mg/m2/day on days 1‐3 and cisplatin 35 mg/m2/day on days 1‐3 (Phase I)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Etoposide 200 mg/m2/day on days 1‐3 and cisplatin 35 mg/m2/day on days 1‐3 (Phase II)
Number of subjects: 48
Study: 1563057

Group type: EXPERIMENTAL
Intervention: Epidural infusions of fentanyl combined with bupivacaine 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural infusions of fentanyl alone
Number of subjects: 0
Study: 3904394

Group type: EXPERIMENTAL
Intervention: Metoprolol, 15 mg intravenously, and 50 mg 4 times a day orally (n = 95)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (n = 95)
Number of subjects: 190
Study: 31746629

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic (1 mU·kg fat‐free mass‐1·min‐1) infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acute hyperoxia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-dose dopamine (1-4 µg·kg‐1·min‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acute hyperoxia + low-dose dopamine
Number of subjects: 18
Study: 29356932

Group type: EXPERIMENTAL
Intervention: cTreatment® (new cryotherapy device)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard cold therapy protocol
Number of subjects: 97
Study: 27156000

Group type: EXPERIMENTAL
Intervention: Equia Fil® with a nanofilled resin coating (n=515)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Fuji IX GP® fast with an LC coating (n=486)
Number of subjects: 643
Study: 25367242

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 50

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 22362136

Group type: EXPERIMENTAL
Intervention: 3D filtered images
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard dose images
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3D filtered images for patients with BMI < 30 kg/m(2)
Number of subjects: 12
Study: 19837490

Group type: EXPERIMENTAL
Intervention: Powder of fertilized eggs (Young Tissue Extract; YTE) for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18851750

Group type: EXPERIMENTAL
Intervention: Acute aneurysmal SAH patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control patients (elective aneurysmal surgery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with Hunt-Hess grades IV to V
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients with grade I-III
Number of subjects: 30
Study: 16019075

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg triamcinolone acetonide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Posterior Sub‐Tenon's capsule injection of 40 mg triamcinolone acetonide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 12
Study: 12425704

Group type: EXPERIMENTAL
Intervention: Memory training (verbal episodic memory; n = 711)
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: Reasoning training (ability to solve problems that follow a serial pattern; n = 705)
Number of subjects: 2832

Group type: EXPERIMENTAL
Intervention: Speed of processing training (visual search and identification; n = 712)
Number of subjects: 2832

Group type: COMPARATOR
Intervention: No-contact control group (n = 704)
Number of subjects: 2832
Study: 10758392

Group type: EXPERIMENTAL
Intervention: Intermittent cold blood cardioplegia with 'hot-shot' (CBC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Continuous warm blood enriched with esmolol (WBE)
Number of subjects: 20
Study: 9190239

Group type: EXPERIMENTAL
Intervention: Patients with symptoms of Löfgren syndrome
Number of subjects: 24

Group type: COMPARATOR
Intervention: Symptomless patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All patient groups
Number of subjects: 24
Study: 1283426

Group type: EXPERIMENTAL
Intervention: Fosinopril, a phosphorus-containing ACE inhibitor, administered as a prodrug.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ACE inhibitors that require dosage adjustment due to renal insufficiency.
Number of subjects: 0
Study: 3929609

Group type: EXPERIMENTAL
Intervention: 2 gm solution of cefamandole
Number of subjects: 223

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 223

Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 223
Study: 31201426

Group type: EXPERIMENTAL
Intervention: Learning multiple skills simultaneously (intervention group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No-contact control group (Study 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Self-control group (Study 2)
Number of subjects: 42
Study: 30699272

Group type: EXPERIMENTAL
Intervention: Alternative vaccination schedule (0-6-50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional vaccination schedule (0-2-6)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 28135975

Group type: EXPERIMENTAL
Intervention: Sorghum group (45g of flaked cereal biscuits daily for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: White wheat group (45g of flaked cereal biscuits daily for 12 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Sorghum and White Wheat)
Number of subjects: 60
Study: 26051348

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) containing 843 mg (‐)‐epigallocatechin‐3‐gallate (EGCG)
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study: 23536256

Group type: EXPERIMENTAL
Intervention: Multimodal intervention in home health settings
Number of subjects: 667

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Automated alert intervention
Number of subjects: 667
Study: 20618719

Group type: EXPERIMENTAL
Intervention: Sensory retraining facial exercises in addition to standard mouth opening exercises
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard of care mouth opening exercises after BSSO
Number of subjects: 186
Study: 18249230

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 15904539

Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease (PD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with cerebellar lesions (CB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurologically healthy controls
Number of subjects: 0
Study: 12752739

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) with counselling visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician preference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low uncertainty about the decision
Number of subjects: 0
Study: 10481420

Group type: EXPERIMENTAL
Intervention: 5% dextrose in Ringer's acetate solution (2 ml)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 2% lidocaine (2 ml)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Normal saline (2 ml) (Control Group)
Number of subjects: 96
Study: 8588396

Group type: EXPERIMENTAL
Intervention: L-Dopa 100 to 200 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 1951872

Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate (500 mg/week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chloroquine diphosphate (1,000 mg/week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Proguanil hydrochloride (200 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 60
Study: 7035578

Group type: EXPERIMENTAL
Intervention: Polysaccharide-protein complex vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0